NCT05846763 Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Follicular Lymphoma in Real World Study
| NCT ID | NCT05846763 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Institute of Hematology & Blood Diseases Hospital, China |
| Condition | Follicular Lymphoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 50 participants |
| Start Date | 2022-11-01 |
| Primary Completion | 2026-05-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 50 participants in total. It began in 2022-11-01 with a primary completion date of 2026-05-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study is planned to prospectively observe and verify the efficacy and safety of induction therapy with obinutuzumab in combination with lenalidomide followed by maintenance therapy with obinutuzumab and lenalidomide in patients with R/R FL in a real-world setting in a Chinese population.
Eligibility Criteria
Patients must meet the following criteria for study entry:: * Signed Informed Consent Form * Age ≥ 18 years at enrollment * At least one prior line of systemic (Stage III-IV) follicular lymphoma therapy * Relapsed or refractory to front-line anti-lymphoma therapy; refractory is defined as: tumor shrinkage of less than 50% or disease progression after 4 cycles of standard regimen chemotherapy; response to standard regimen chemotherapy, relapse within 24 months; 2 or more relapses, meeting one of the above criteria as refractory lymphoma. * Conditional treatment with obinutuzumab in combination with lenalidomide Exclusion Criteria: * Patients currently participating or planning to participate in any interventional clinical trial * Any other reason that, in the opinion of the investigator, makes the patient unsuitable for this study
Contact & Investigator
Shuhua Yi, Dr
PRINCIPAL INVESTIGATOR
Institute of Hematology & Blood Diseases Hospital, Chinese
Frequently Asked Questions
Who can join the NCT05846763 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Follicular Lymphoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05846763 currently recruiting?
Yes, NCT05846763 is actively recruiting participants. Contact the research team at yishuhua@ihcams.ac.cn for enrollment information.
Where is the NCT05846763 trial being conducted?
This trial is being conducted at Tianjin, China.
Who is sponsoring the NCT05846763 clinical trial?
NCT05846763 is sponsored by Institute of Hematology & Blood Diseases Hospital, China. The principal investigator is Shuhua Yi, Dr at Institute of Hematology & Blood Diseases Hospital, Chinese. The trial plans to enroll 50 participants.